TY  - JOUR
AU  - Pérez-Lescure Picarzo, Javier
AU  - Centeno Malfaz, Fernando
AU  - Collell Hernández, Rosa
AU  - Crespo Marcos, David
AU  - Fernández Soria, Teresa
AU  - Manso García, Begoña
AU  - Rojo Sombrero, Henar
AU  - Sabaté Rotés, Anna
AU  - Sarquella-Brugada, Georgia
PY  - 2019
DO  - 10.1016/j.anpedi.2019.09.002
UR  - http://hdl.handle.net/10668/14619
T2  - Anales de pediatria
AB  - Approved drugs for attention deficit hyperactivity disorder (ADHD) in Spain are methylphenidate, lisdexamphetamine, atomoxetine and guanfacine. Due to adverse cardiovascular effects, mainly increased blood pressure and heart rate, its use in patients...
LA  - es
KW  - Acquired heart disease
KW  - Atomoxetina
KW  - Atomoxetine
KW  - Cardiopatías adquiridas
KW  - Cardiopatías congénitas
KW  - Cardiovascular side effects
KW  - Congenital heart defects
KW  - Efectos secundarios cardiovasculares
KW  - Guanfacina
KW  - Guanfacine
KW  - Lisdexamphetamine
KW  - Lisdexanfetamina
KW  - Methylphenidate
KW  - Metilfenidato
KW  - Muerte súbita
KW  - Sudden death
KW  - Adolescent
KW  - Attention Deficit Disorder with Hyperactivity
KW  - Child
KW  - Drug-Related Side Effects and Adverse Reactions
KW  - Heart Defects, Congenital
KW  - Humans
KW  - Spain
TI  - [Recommendations of the Spanish Society of Paediatric Cardiology and Congenital Heart Disease as regards the use of drugs in attention deficit hyperactivity disorder in children and adolescents with a known heart disease, as well as in the general paediatric population: Position statement by the Spanish Paediatric Association].
T2  - Recomendaciones de la Sociedad Española de Cardiología Pediátrica y Cardiopatías Congénitas en relación con el uso de medicamentos en el trastorno por déficit de atención e hiperactividad en niños y adolescentes con cardiopatías conocidas y en la población pediátrica general, posicionamiento de la Asociación Española de Pediatría.
TY  - research article
VL  - 92
ER  -